Bladder Cancer

Stephen B. Williams, MD, MS, discusses a recent study evaluating costs of surgical treatments for bladder cancer.

Program encompasses patient counseling, anesthetic planning, and early mobilization.

Presurgical treatment with the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab showed promise in cisplatin-ineligible patients with high-risk localized bladder cancer.

The antibody-drug conjugate was highly active in patients who received a PD-1/PD-L1 inhibitor but were ineligible for cisplatin.

The sensitivity rate for the detection of urothelial carcinoma with the UroCAD urine-based liquid biopsy far exceeded the rate with urine cytology.

The OASIS trial is examining the capability of the RENOVA iStim implantable tibial neuromodulation system to reduce urinary urgency incontinence episodes.

"Currently, there is significant variability in the design, conduct, and analysis of clinical trials for adjuvant treatment of both kidney cancer and bladder cancer. This variability negatively affects our ability to interpret trial results," said Richard Pazdur, MD.

Dual immune checkpoint blockade with the PD-1 inhibitor tislelizumab and the PD-L1 inhibitor BGB-A333 showed clinical activity in bladder cancer.

The antibody-drug conjugate is used for the second-line treatment of patients with HER2-positive locally advanced or metastatic urothelial carcinoma.

An analysis from the pivotal phase 3 JAVELIN Bladder 100 trial showed that the survival benefit observed with frontline maintenance avelumab in the overall population was sustained across several prespecified patients subgroups.

The addition of avelumab to standard first-line gemcitabine/carboplatin did not improve outcomes in patients with metastatic urothelial carcinoma.

The positive findings could make nivolumab the new standard of care in the adjuvant setting for patients with muscle-invasive urothelial cancer.

The antibody-drug conjugate enfortumab vedotin significantly improved overall survival versus chemotherapy in a phase 3 trial.

Pivotal phase 3 trial launched to confirm promising results in metastatic urothelial carcinoma.

Of 2463 patients with urothelial cancer who underwent comprehensive genomic profiling, 39% harbored ≥1 tier 1-2 genomic alterations.

“The grasper disposable scope may fill the gap as an alternative to the conventional reusable cystoscope,” researchers concluded.

Tele-cystoscopy was found equivalent to traditional cystoscopy with respect to identification of abnormalities and action decisions.

Differences following surgery were related to the control of cancer and adjustments with urinary diversion.

"Therapeutic strategies are needed in the management of NMIBC that recurs after gold-standard intravesical BCG," Gomella writes.

Investigators warn of the dangers of overprescribing antibiotics in cancer care.

The new dose would reduce a patient’s required medical visits by 50%.

Increased usage of bladder diagrams was observed following implementation of the program.

Including the genomic test in the protocol for patient surveillance reduced the average number of annual cystoscopies by approximately 39%.

The cost-savings are particularly noteworthy given prior evidence of blue light imaging enhancing the efficacy of diagnostic cystoscopy.

A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.